alpha-chymotrypsin and Neoplasm-Metastasis

alpha-chymotrypsin has been researched along with Neoplasm-Metastasis* in 21 studies

Trials

1 trial(s) available for alpha-chymotrypsin and Neoplasm-Metastasis

ArticleYear
Double-blind pilot-study on the efficacy of enzyme therapy in advanced colorectal cancer.
    Przeglad lekarski, 2000, Volume: 57 Suppl 5

    All tested variables showed a tendency in favor for Wobe-Mugos E therapy as addition to standard therapy. Enzymes improve the quality of life by reducing cancer disease typical symptoms, they reduce side effects of chemo-/radiotherapy and they have a potential of prolonging life (preliminary data only).

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chymotrypsin; Colorectal Neoplasms; Disease-Free Survival; Double-Blind Method; Drug Combinations; Fluorouracil; Humans; Levamisole; Neoplasm Metastasis; Pancreatic Extracts; Papain; Pilot Projects; Quality of Life; Survival Rate; Thymus Extracts; Trypsin

2000

Other Studies

20 other study(ies) available for alpha-chymotrypsin and Neoplasm-Metastasis

ArticleYear
Changes in proteasome chymotrypsin-like activity during the development of human mammary and thyroid carcinomas.
    Bulletin of experimental biology and medicine, 2013, Volume: 156, Issue:2

    Changes in the proteasome chymotrypsin-like activity in mammary and thyroid carcinomas in comparison with the adjacent tissue were studied at stages T(1-4)N(0-3)M(0) and T(2-3)N(0-1)M(0), respectively. The activities changed in a wave-like manner over the course of mammary carcinoma growth in cases with and without metastases. The minimum increment of the activity in the tumor was recorded during the T(2)N(0) stage in the absence of local metastases. The increment of the activity reached the peak in N(1) tumors of the same size with metastases. The activities in the tumor and adjacent tissues virtually did not differ during the T(3-4)N(1-3) stages. The time course of proteasome activity changes in thyroid tumors of the studied stages was similar to that in mammary carcinoma. The results can be used for development of methods for evaluating the aggressiveness of mammary and thyroid tumors.

    Topics: Boronic Acids; Bortezomib; Breast; Breast Neoplasms; Chymotrypsin; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Metastasis; Neoplasm Staging; Proteasome Endopeptidase Complex; Pyrazines; Thyroid Gland; Thyroid Neoplasms

2013
Effect of chymotrypsin C and related proteins on pancreatic cancer cell migration.
    Acta biochimica et biophysica Sinica, 2011, Volume: 43, Issue:5

    Pancreatic cancer is a malignant cancer with a high mortality rate. The amount of chymotrypsin C in pancreatic cancer cells is only 20% of that found in normal cells. Chymotrypsin C has been reported to be involved in cancer cell apoptosis, but its effect on pancreatic cancer cell migration is unclear. We performed cell migration scratch assays and Transwell experiments, and found that cell migration ability was downregulated in pancreatic cancer Aspc-1 cells that overexpressed chymotrypsin C, whereas the cell migration ability was upregulated in Aspc-1 cells in which chymotrypsin C was suppressed. Two-dimensional fluorescence differential in gel electrophoresis/mass spectrometry method was used to identify the proteins that were differentially expressed in Aspc-1 cells that were transfected with plasmids to induce either overexpression or suppressed expression of chymotrypsin C. Among 26 identified differential proteins, cytokeratin 18 was most obviously correlated with chymotrypsin C expression. Cytokeratin 18 is expressed in developmental tissues in early stages of cancer, and is highly expressed in most carcinomas. We speculated that chymotrypsin C might regulate pancreatic cancer cell migration in relation to cytokeratin 18 expression.

    Topics: Base Sequence; Chymotrypsin; DNA Primers; Electrophoresis, Gel, Two-Dimensional; Humans; Neoplasm Metastasis; Pancreatic Neoplasms; Polymerase Chain Reaction; Tumor Cells, Cultured

2011
Crystal structure of Kunitz domain 1 (KD1) of tissue factor pathway inhibitor-2 in complex with trypsin. Implications for KD1 specificity of inhibition.
    The Journal of biological chemistry, 2005, Jul-29, Volume: 280, Issue:30

    Kunitz domain 1 (KD1) of tissue factor pathway inhibitor-2 inhibits trypsin, plasmin, and factor VIIa (FVIIa)/tissue factor with Ki values of 13, 3, and 1640 nM, respectively. To investigate the molecular specificity of KD1, crystals of the complex of KD1 with bovine beta-trypsin were obtained that diffracted to 1.8 A. The P1 residue Arg-15 (bovine pancreatic trypsin inhibitor numbering) in KD1 interacts with Asp-189 (chymotrypsin numbering) and with the carbonyl oxygens of Gly-219 and Ogamma of Ser-190. Leu-17, Leu-18, Leu-19, and Leu-34 in KD1 make van der Waals contacts with Tyr-39, Phe-41, and Tyr-151 in trypsin, forming a hydrophobic interface. Molecular modeling indicates that this complementary hydrophobic patch is composed of Phe-37, Met-39, and Phe-41 in plasmin, whereas in FVIIa/tissue factor, it is essentially absent. Arg-20, Tyr-46, and Glu-39 in KD1 interact with trypsin through ordered water molecules. In contrast, insertions in the 60-loop in plasmin and FVIIa allow Arg-20 of KD1 to directly interact with Glu-60 in plasmin and Asp-60 in FVIIa. Moreover, Tyr-46 in KD1 electrostatically interacts with Lys-60A and Arg-60D in plasmin and Lys-60A in FVIIa. Glu-39 in KD1 interacts directly with Arg-175 of the basic patch in plasmin, whereas in FVIIa, such interactions are not possible. Thus, the specificity of KD1 for plasmin is attributable to hydrophobic and direct electrostatic interactions. For trypsin, hydrophobic interactions are intact, and electrostatic interactions are weak, whereas for FVIIa, hydrophobic interactions are missing, and electrostatic interactions are partially intact. These findings provide insight into the protease selectivity of KD1.

    Topics: Animals; Cattle; Chymotrypsin; Crystallography, X-Ray; Escherichia coli; Factor VIIa; Fibrinolysin; Glycoproteins; Humans; Leucine; Models, Molecular; Neoplasm Metastasis; Oxygen; Phenylalanine; Protease Inhibitors; Protein Binding; Protein Conformation; Protein Structure, Secondary; Protein Structure, Tertiary; Serine; Static Electricity; Trypsin

2005
Impact of complementary oral enzyme application on the postoperative treatment results of breast cancer patients--results of an epidemiological multicentre retrolective cohort study.
    Cancer chemotherapy and pharmacology, 2001, Volume: 47 Suppl

    [corrected] To evaluate the impact of postoperative treatment with an oral enzyme (OE) preparation given complementary to an antineoplastic therapy in patients with breast cancer.. The design of this epidemiological study was a retrolective cohort analysis with parallel groups. Design and conduct of the study were performed to current standards for prospective, controlled clinical trials. A cohort of 2,339 breast cancer patients undergoing surgical intervention and radio-, chemo- or hormonal therapy were studied in 216 centres. Of the 2,339 patients, 1,283 received complementary treatment with OE and 1,056 did not receive OE. Patients with other complementary medications were excluded and the final analysis was performed with the data from 649 patients, of whom 239 (37%) were additionally treated with OE (test group) and 410 (63%) without OE (control group). The median follow-up time for the test group was 485 days and for the control group 213 days. The primary endpoint of the study was to determine whether complementary treatment with OE can reduce typical disease- or therapy-associated signs and symptoms (gastrointestinal symptoms, mental symptoms, dyspnoea, headache, tumour pain, cachexia, skin disorders, infections, and side effects associated with the antineoplastic therapy) in patients with breast cancer. Imbalances for causal effects (covariates) were adjusted for by means of the propensity score. Outcome analysis was performed by estimating the linear regression between change in symptom score and propensity score with all data and using this regression line to calculate the change in symptom score which would be expected for each patient. Tumour-associated events (recurrence, metastasis, and death) were evaluated in terms of the number of events observed and time to event. The safety of treatment with OE was analysed in terms of the number and severity of adverse events, their duration, treatment and outcome.. For all symptoms except tumour pain, the adjusted mean improvement in symptom scores was larger in the test group than in the control group. The adjusted difference was statistically significant for all symptoms, except tumour pain and infections. The results show that the typical disease- and therapy-associated signs and symptoms in patients on complementary therapy with OE during postoperative treatment were significantly less. For 75% of the test group and 55% of the control group the physician recorded "no signs and symptoms". A clear reduction in the side effects of radiotherapy and chemotherapy was documented in 74% of the test group and 55% of the control group. Analysis of survival, recurrence, and metastasis demonstrated a reduced number of events in the test group. There was evidence of a beneficial influence of OE on time to event, although the median observation time was too short in these breast cancer patients to draw definite conclusions. The safety component was judged in 98% of the test group and 76% of the control group as "very good" or "good". In the total sample of 2,339 patients, the rate of OE-associated adverse reactions was 3.2%. All side effects were mild to moderate gastrointestinal symptoms.. Complementary treatment of breast cancer patients with OE improves the quality of life by reducing signs and symptoms of the disease and the side effects of adjuvant antineoplastic therapies. This epidemiological retrolective cohort analysis provides evidence that the patients may also gain benefit by a prolongation of the time to event for cancer recurrence, metastasis and survival. OE was generally well tolerated.

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Breast Neoplasms; Chemotherapy, Adjuvant; Chymotrypsin; Cohort Studies; Drug Combinations; Endopeptidases; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Papain; Postoperative Care; Quality of Life; Radiotherapy, Adjuvant; Retrospective Studies; Treatment Outcome; Trypsin

2001
Proteinases reduce metastatic dissemination and increase survival time in C57Bl6 mice with the Lewis lung carcinoma.
    Life sciences, 1998, Volume: 63, Issue:17

    The effect of combined proteolytic enzymes, administered by the rectal route, on the metastatic process and the time of survival in C57Bl6 mice with the Lewis lung carcinoma inoculated subcutaneously was investigated. In the control group, which received no enzyme treatment, 90% of animals died of the metastatic spread of cancer by day 18 after primary tumor extirpation. In Group A, which received the multi-enzyme solution from the time of primary tumor extirpation, 30% of mice died of disseminated cancer by day 25. In Group B, which was treated with the enzymes from 6 days before primary tumor extirpation, only 10% of animals showed the metastatic process by day 15. In Group C, which received the enzymes from 24 hours after intracutaneous tumor inoculation, no metastatic dissemination was discernible. In these three groups, the enzyme treatment was carried out throughout the study. None of the control animals survived for 100 days when the study was ended. The treated groups A, B and C showed survival rate 60%, 90% and 100% of animals, respectively, by 100 days.

    Topics: Administration, Rectal; Animals; Carcinoma, Lewis Lung; Chymotrypsin; Drug Combinations; Endopeptidases; Female; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; Neoplasm Transplantation; Pancreatic Extracts; Papain; Skin Neoplasms; Survival Rate; Thymus Extracts; Trypsin

1998
Antimetastatic activity of boro-amino acid analog protease inhibitors against B16BL6 melanoma in vivo.
    Invasion & metastasis, 1992, Volume: 12, Issue:5-6

    Di- and tripeptide boro-amino acid analog protease inhibitors with specificity for chymotrypsin and elastase decrease the number of melanotic foci formed in the lungs of mice in the B16BL6 experimental metastatic tumor model. These effects were at significantly lower concentration than leupeptin or other natural chymotrypsin inhibitors previously reported. These results support the involvement of elastase and chymotrypsin in the metastatic process.

    Topics: Animals; Boronic Acids; Cell Division; Chymotrypsin; Melanoma, Experimental; Mice; Mice, Inbred Strains; Neoplasm Metastasis; Pancreatic Elastase; Serine Proteinase Inhibitors; Tumor Cells, Cultured

1992
Differential release of active proteinase inhibitors by two rat mammary adenocarcinoma variants possessing different metastatic potentials.
    Cancer research, 1991, Feb-15, Volume: 51, Issue:4

    The ability of tumor cells to express elevated levels of proteinases capable of degrading tissue matrix and basement membrane components in vitro has been correlated to their invasive and metastatic potential. Many in vitro invasion assays have been performed either in the presence of serum or with tumor cells that had been previously grown in serum. Since serum contains large amounts of active proteinase inhibitors, their presence could complicate interpretations. We have, therefore, attempted to measure the amounts of serine proteinase inhibitors released into culture medium by two rat mammary adenocarcinoma metastatic variants selected in vitro for serum-independent growth and differing in their in vivo metastatic behavior. Concentrated spent media (CSM) derived from cultures of poorly metastatic MTLn2(T42D) and highly metastatic MTLn3(T17D) tumor cells, grown in the presence and absence of fetal bovine serum (FBS) for 20-24 h, were compared for the presence of serine proteinase inhibitors capable of inactivating alpha-chymotrypsin. Our results show that when MTLn2(T42D) and MTLn3(T17D) tumor cells were exposed to FBS, the CSM of MTLn2(T42D) exhibited nearly 5-fold greater amounts of active proteinase inhibitors than that of MTLn3(T17D). The amount of proteinase inhibitory activity detected in the CSM of tumor cells not exposed to FBS was not eliminated but declined by 82% and 37% for MTLn2(T42D) and MTLn3(T17D), respectively. Analysis for enzyme-inhibitor (E-I) complex formation by nonreducing sodium dodecyl sulfate-polyacrylamide gel electrophoresis followed by autoradiography confirmed the kinetic results and revealed that the major inhibitor present in CSM/FBS of both variants forms a heat- and sodium dodecyl sulfate-stable E-I complex with an apparent molecular weight of approximately 79,000, identical to that formed when FBS or purified alpha 1-proteinase inhibitor is incubated with [alpha-125I]chymotrypsin. E-I complexes with apparent molecular weights of 44,000 and 50,000 were formed from CSM/bovine serum albumin of MTLn3(T17D) and MTLn2(T42D), respectively, that were not detected when [alpha-125I]chymotrypsin was incubated with bovine serum albumin. We infer from these observations that, in culture, poorly metastatic MTLn2(T42D) tumor cells, as compared to their highly metastatic MTLn3(T17D) counterparts, exhibit an increased capacity to retain and subsequently release significantly greater amounts of serum-derived active proteinase inhibitors

    Topics: Adenocarcinoma; Animals; Chymotrypsin; Electrophoresis, Polyacrylamide Gel; Female; Lung Neoplasms; Mammary Neoplasms, Experimental; Neoplasm Invasiveness; Neoplasm Metastasis; Rats; Rats, Inbred F344; Serine Proteinase Inhibitors

1991
Spontaneous capillary tube migration of metastatic rat mammary adenocarcinoma cells.
    Invasion & metastasis, 1984, Volume: 4, Issue:2

    The spontaneous capillary tube migration of metastatic MAT 13762 rat mammary adenocarcinoma cells has been measured and compared with that of a non-metastatic variant, TGR. MAT 13762 cells migrated to a greater extent in the presence than in the absence of serum, and in both cases migration areas were considerably greater than for TGR cells. Different clones of hybrids, formed by fusing metastatic and non-metastatic variants, showed migration areas ranging from those of the metastatic to those of the non-metastatic parent cells. Despite their differing migrations, all of these clones were either non or only slightly metastatic. Treatment of TGR cells with trypsin enhanced their migration to that of MAT 13762 cells, whereas trypsin-treated MAT 13762 cells showed a slightly decreased migration. Although MAT 13762 cells, unlike TGR cells, produced large amounts of plasminogen activator (PA), no evidence was obtained for the direct involvement of PA in the high migration rate of MAT 13762 cells.

    Topics: Adenocarcinoma; Animals; Cell Line; Cell Movement; Chymotrypsin; Colchicine; Female; Mammary Neoplasms, Experimental; Neoplasm Metastasis; Plasminogen Activators; Rats; Rats, Inbred F344; Trypsin

1984
[Malignant fibrous histiocytoma of the lung. Case report, review of literature and differential diagnostic aspects].
    Der Pathologe, 1983, Volume: 4, Issue:6

    Topics: Aged; alpha 1-Antichymotrypsin; alpha 1-Antitrypsin; Chymotrypsin; Diagnosis, Differential; Histiocytoma, Benign Fibrous; Humans; Lung; Lung Neoplasms; Male; Neoplasm Metastasis; Protease Inhibitors

1983
Multivariate analyses as aids to diagnosis and assessment of prognosis in gastrointestinal cancer.
    British journal of cancer, 1983, Volume: 48, Issue:3

    The role of carcinoembryonic antigen (CEA), gamma glutamyl transpeptidase (gamma GT), phosphohexose isomerase (PHI), pseudouridine (psi) and acute phase reactant proteins (C-reactive protein (CRP) alpha 1-antichymotrypsin (ACT) and alpha 1-acid glycoprotein (AGP] in assessing the prognosis of gastrointestinal neoplasms and the discriminant function in distinguishing benign from malignant diseases of the GI tract was examined. In stomach cancer pre-operative levels of CRP can help in the identification of the patients with a resectable tumour; the pre-operative biochemical measurements do not give any further information on prognosis once stage and site are taken into account. In colorectal cancer pre-operative ACT levels give additional prognostic information once the clinical factors, Dukes stage, sex and age have been accounted for; PHI levels are on the border line of significance. A discriminant function has been devised using sex, CEA, psi, gamma GT, ACT and PHI that can identify 89% of Dukes "D" patients prior to surgery with a misclassification of 7% of other cases of colorectal cancer. A discriminant function using all the biochemical variates separated the cancer from non-cancer patients. The false positive rate for cancer was 16% and a false negative rate of 19%, when the cut-off level was set at 0.7.

    Topics: Adult; Aged; alpha 1-Antichymotrypsin; C-Reactive Protein; Chymotrypsin; Diagnosis, Differential; Female; Gastrointestinal Diseases; Gastrointestinal Neoplasms; Glucose-6-Phosphate Isomerase; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Regression Analysis

1983
Biochemical and biological properties of leukocyte intracellular inhibitors of proteinases.
    Advances in experimental medicine and biology, 1979, Volume: 121, Issue:A

    Topics: Animals; Cathepsins; Cell Transformation, Neoplastic; Chemical Phenomena; Chemistry; Chromatography, Gel; Chymotrypsin; Hydrogen-Ion Concentration; Leukocytes; Neoplasm Metastasis; Pancreatic Elastase; Protease Inhibitors; Swine

1979
Hydrolytic enzyme activities, migratory activity, and in vivo growth and metastatic potential of recent tumor isolates.
    Cancer research, 1979, Volume: 39, Issue:7 Pt 1

    Topics: Animals; Cell Movement; Chymotrypsin; Clone Cells; Esterases; Female; Fibrosarcoma; Glucuronidase; Glycoside Hydrolases; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; Neoplasm Transplantation; Sarcoma, Experimental

1979
Acute phase reactant proteins in the clinical management of carcinoma of the bladder.
    British journal of urology, 1979, Volume: 51, Issue:4

    The levels of a number of acute phase reactant proteins have been measured in 250 patients with carcinoma of the bladder in all stages. Three of them, acid glycoprotein, antichymotrypsin, and C-reactive protein, frequently gave abnormal results in advanced disease. The levels of these 3 proteins in patients who were clinically tumour-free were not distinguishable from those from an age-matched control group. The levels in patients with T1 and T2 bladder tumours were sometimes elevated. In advanced disease, figures were commonly above the normal range.

    Topics: Adult; C-Reactive Protein; Chymotrypsin; Glycoproteins; Humans; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Urinary Bladder Neoplasms

1979
[Determination of chymotrypsin in the stool in chronic pancreatic diseases associated with exocrine insufficiency].
    Wiener medizinische Wochenschrift (1946), 1976, Mar-26, Volume: 126, Issue:13-14

    Topics: Adult; Aged; Chronic Disease; Chymotrypsin; Feces; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Diseases; Pancreatic Neoplasms; Pancreatitis

1976
Proceedings: Esterase activity of carcinoembryonic antigen.
    Cancer research, 1974, Volume: 34, Issue:8

    Topics: Adenocarcinoma; Adenosine Triphosphatases; Alkaline Phosphatase; Carboxypeptidases; Carcinoembryonic Antigen; Chymotrypsin; Colonic Neoplasms; Cystinyl Aminopeptidase; Esterases; Glucuronidase; Humans; Liver Neoplasms; Neoplasm Metastasis; Sulfatases

1974
Regional perfusion and circulation-stop method for chemotherapy of cancer and metastasis.
    Gan, 1974, Volume: 65, Issue:3

    Topics: Animals; Antineoplastic Agents; Azirines; Carbamates; Chemotherapy, Cancer, Regional Perfusion; Chymotrypsin; Fibrinolytic Agents; Injections, Intramuscular; Injections, Intravenous; Neoplasm Metastasis; Neoplasms; Quinones; Rabbits

1974
Pancreatic enzyme inhibitors in health and disease.
    American journal of clinical pathology, 1971, Volume: 55, Issue:4

    Topics: Adult; Aged; Breast Neoplasms; Carcinoma; Cholecystitis; Chymotrypsin; Colorimetry; Duodenal Ulcer; Female; Hepatitis; Humans; Intestinal Diseases; Liver Cirrhosis; Lung Diseases; Lung Diseases, Obstructive; Male; Middle Aged; Neoplasm Metastasis; Pancreatitis; Pregnancy; Respiratory Tract Infections; Trypsin Inhibitors

1971
Pharmacological characteristics of the antidiuretic principle in a bronchogenic carcinoma from a patient with hyponatremia.
    The Journal of clinical endocrinology and metabolism, 1967, Volume: 27, Issue:10

    Topics: Animals; Anura; Biological Assay; Carcinoma, Bronchogenic; Chromatography, Gel; Chromatography, Ion Exchange; Chymotrypsin; Diuresis; Hormones, Ectopic; Humans; Hyponatremia; Liver Neoplasms; Lymphatic Metastasis; Neoplasm Metastasis; Pancreatic Neoplasms; Thioglycolates; Trypsin; Vasopressins

1967
Experimental studies on the combined chemotherapy with anticoagulant and anticancer agent.
    Nihon geka hokan. Archiv fur japanische Chirurgie, 1967, Sep-01, Volume: 36, Issue:5

    Topics: Animals; Chymotrypsin; Heparin; Kidney; Liver; Lung; Mitomycins; Neoplasm Metastasis; Rats; Sarcoma, Yoshida

1967
EXFOLIATIVE CYTOLOGICAL SCREENING FOR GASTRIC CANCER.
    Cancer, 1964, Volume: 17

    Topics: Achlorhydria; Adenocarcinoma; Anemia; Anemia, Pernicious; Chymotrypsin; Cytodiagnosis; Gastric Acidity Determination; Gastroscopy; Geriatrics; Humans; Mass Screening; Neoplasm Metastasis; Radiography; Stomach Neoplasms; Surgical Procedures, Operative

1964
chemdatabank.com